“Grail's stock declined after its cancer screening test failed to meet its early-stage endpoints, though it succeeded in detecting stage 3 cases. The manager believes upcoming clinical presentations will clarify the data, trigger a stock recovery, and support the long-term potential of the company's technology.”
Each excerpt above is the manager's commentary on this ticker specifically. The full letter has the rest of their portfolio thinking, risk discussion, and broader institutional context.